Molina Healthcare's stock experienced a sharp after-hours plunge of 6.30% following the release of its second-quarter 2026 financial results. The decline came despite the company's adjusted earnings per share of $1.51 slightly surpassing the consensus estimate of $1.39.

The selloff was primarily driven by a severe deterioration in year-over-year profitability. Molina reported a 74% drop in GAAP earnings per share to $1.19, with revenue declining 4.8% to $10.87 billion. The medical care ratio, a key profitability metric, widened significantly to 92.2%, indicating increased costs relative to premiums collected.

Investor sentiment was further weighed down by concerning elements within the company's full-year guidance. Molina disclosed that its traditional Medicare Advantage Prescription Drug (MAPD) products are underperforming expectations, projecting a $1.00 per share earnings drag. Additionally, the implementation of a new Florida Medicaid contract in the fourth quarter is expected to contribute a loss of $1.50 per share. These specific headwinds overshadowed the modest top- and bottom-line beats, triggering the post-earnings decline.